Immix Biopharma Investor Presentation Deck

Neurotoxicity Restricts CAR-T Adoption Parkinson's Like Symptoms (can develop after 3 months) Limited Hospital Access (can only be dosed in 5% hospitals in the US) CAR-T Neurotoxicity Long Hospital Stay (average -14 days) Memorial Sloan Kettering Cancer Center ●●● IMMIX S BIOPHARMA AACR American Association for Cancer Research CANCER DISCOVERY "Chimeric antigen receptor (CAR) T-cell therapy is highly effective... but is hindered by neurotoxicity." Patient Deaths (On FDA Appproval Labels) doi: 10.1158/2159-8290.CD-17-1319 7

View entire presentation